UroLift™ System – APAC

The UroLift™ System – APAC is a minimally invasive treatment for lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH), a common condition in men. Developed by NeoTract, Inc., a Teleflex company, this system is available in the Asia-Pacific region and other global markets. The UroLift™ System uses a specialized device to place small permanent implants that lift the enlarged prostate tissue away from the urethra, allowing for improved urinary flow without cutting or removing tissue. This outpatient procedure is typically performed under local anesthesia, enabling patients to return home quickly without the need for a catheter. The latest version, the UroLift™ 2 System, offers enhanced precision for physicians and is suitable for men with prostate sizes up to 100 grams. This treatment is designed for men aged 45 and older who are looking for alternatives to medication or major surgery, particularly those concerned about preserving sexual function and quality of life. The UroLift™ System provides effective symptom relief and a quick recovery, making it a preferred option for managing BPH.

• Employees 2
• Founded 2004
• Annual Revenue $15300000